Sun Pharmaceutical Industries Ltd. has announced that USFDA has granted approval for the Abbreviated New Drug Application (ANDA) to market a generic version of MedImmune’s Ethyol®, amifostine for injection 500mg.
This generic amifostine for injection is therapeutically equivalent to MedImmune’s Ethyol® amifostine for injection 500mg. Ethyol® has annual sales of approximately USD 80 million in the US. Sun Pharma, being the first-to-file an ANDA for generic Ethyol® with a para IV certification, has a 180-day marketing exclusivity.
Ethyol® is covered under 3 patents - ‘471 (July 31, 2012), ‘731 (July 31, 2012) and ‘409 (Dec 8, 2017). This ANDA was filed with para IV certification against all the patents. Medimmune filed a suit in the District Court of Maryland and the case is under litigation.
Amifostine is used as an adjuvant in cancer treatment. Sun Pharma’s amifostine for injection will be indicated for the reduction of kidney damage in patients who have advanced ovarian cancer and are being given repeat doses of cisplatin.
Ethyol® is a registered trademark of MedImmune Oncology, Inc.About Sun Pharmaceutical Industries Ltd.
Established in 1983, listed since 1994 and headquartered in India, Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO,Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE: 524715) is an international, integrated, speciality pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world. In India, the company is a leader in niche therapy areas of psychiatry, neurology,cardiology, diabetology, gastroenterology, and orthopedics. The company has strong skills in product development, process chemistry, and manufacturing of complex API, as well as dosage forms.
